Evidence map›Paper›PMID 36975468›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.

Sanila Sarkar, Whitney Throckmorton, Racheal Bingham, Pavlos Msaouel, Giannicola Genovese, John Slopis, Priya Rao, Zsila Sadighi, Cynthia E Herzog

Open access · goldFull text readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sanila SarkarMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.
Whitney ThrockmortonMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.
Racheal BinghamMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.
Pavlos MsaouelMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.ORCID 0000-0001-6505-8308
Giannicola GenoveseMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.
John SlopisMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.
Priya RaoMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.
Zsila SadighiMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.
Cynthia E HerzogMD Anderson Cancer Care Center, University of Texas, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672NIH HHS P30 CA016672
6 · The paper itself

Abstract

We present, to our knowledge, the first reported case of germline neurofibromatosis Type 2 (NF2) associated with renal cell carcinoma unclassified with medullary phenotype (RCCU-MP) with somatic loss by immunohistochemistry of the

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMeningeal NeoplasmsMeningiomaNeurofibromatosis 2FemaleHumansNeurofibromin 2PhenotypeNeurofibromin 2NF2 protein, humanmedullary phenotypeNF2renal cell carcinoma

Identifiers

PMID36975468
PMCPMC10047671
OpenAlexW4324141295

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read11
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.